ArticleEuropean radiology2025
Comparison of volumetric and linear measurements of intestinal inflammation and treatment response in children with newly diagnosed ileal Crohn disease.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Imaging endpoints in inflammatory bowel disease: current evidence and future directions for ultrasound and MRI.BMC medicine · 2026Review
- CD27 and GZMK as Co-Biomarkers in Rheumatoid Arthritis and Crohn's Disease and Mediate Immune ImbalanceEndocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo compare the responsiveness of linear and volumetric assessments of intestinal inflammation in children with newly diagnosed ileal Crohn disease (CD) into treatment. MATERIALS AND
methodsTwenty children with ileal CD (8 girls; mean age = 14.0 years) between May 2019 and April 2021 underwent research MRI at three time points-diagnosis, 6 weeks, and 6 months into treatment. For each examination, a radiologist measured the maximum wall thickness and length of disease. Then, the inflamed ileum was manually and semi-automatically segmented to measure the tissue volume. Mixed-effects models were used to assess the changes over time. Intra-class correlation was used to assess agreement between manual and semi-automated segmentation.
resultsLength of disease decreased with medical treatment (19.2 vs. 12.2 vs. 8.0 cm; p = 0.002), 36% from baseline to 6 weeks and 58% from baseline to 6 months, while maximum bowel wall thickness also decreased over time (7.6 vs. 5.8 vs. 4.5 mm; p < 0.0001), 24% from baseline to 6 weeks and 41% from baseline to 6 months. Manual volumetric measurements demonstrated a significant treatment response (19.8 vs.11.6 vs.5.1 mL; p < 0.0001), 41% decrease from baseline to 6 weeks and 74% from baseline to 6 months. Using semi-automated segmentation, the volume decreased significantly over time as well (24.0 vs.15.1 vs.9.1 mL; p = 0.0007), 37% from baseline to 6 weeks and 62% from baseline to 6 months. There was good agreement between manual and semi-automated volumetric assessments (ICC = 0.78 [95% CI: 0.57-0.88]).
conclusionVolumetric measurement of inflammation is responsive to medical treatment in CD and, as percentage compared to baseline, may show greater treatment response than linear measurements. KEY POINTS: Question Volumetric measurements of intestinal inflammation related to Crohn disease may be superior to traditional linear measurements. Findings Volumetric measurements showed greater treatment response when compared to linear measurements, and there was good agreement between manual and semi-automated volumetric measurements of intestinal inflammation. Clinical relevance Volumetric assessment is a promising tool that may provide a novel biomarker for evaluating intestinal inflammation and treatment response in Crohn Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.